|
Purpose: The purpose of this study is to understand the neoadjuvant chemotherapy for advanced cervical cancer, the postoperative adverse prognostic factors (such as vaginal margin, parametrial invasion, vascular invasion, lymph node-positive rate, etc.) impact and neoadjuvant chemotherapy-induced adverse reactions, and explore its clinical significance. Methods: First Hospital of Jilin University, January 2007 - January 2011 among 100 patients with advanced cervical cancer clinical data, including preoperative neoadjuvant chemotherapy patients accounted for 30 cases, 70 cases of direct surgical patients as controls groups. Using descriptive, retrospective comparative analysis method, applied EXCEL software to build a database, application SPSS17.0 software χ2 test and t test statistical analysis of 100 patients with advanced cervical cancer clinical data, analyzing patients undergoing neoadjuvant chemotherapy, surgery directly The clinical characteristics of various stages, tumor type, pathological grade of cervical cancer chemotherapy response analysis of two ways neoadjuvant chemotherapy clinical efficacy response, adverse prognostic factors and adverse reactions, in two different ways chemotherapy number of chemotherapy treatments, chemotherapy, surgery time interval, the maximum diameter of the tumor before and after chemotherapy were compared. Results: (1) through the femoral artery chemotherapy after surgery group and intravenous chemotherapy after surgery in patients Ⅰ B2 phase, Ⅱ A period, Ⅱ B patients ratio statistically significant, the former Ⅱ B the majority of patients, while the latter Ⅱ A patient in the majority, Overall, through the femoral artery surgery patients after chemotherapy serious condition; cervical cancer patients undergoing neoadjuvant chemotherapy in patients with immediate surgery group no significant difference in age, comparable. (2) of neoadjuvant chemotherapy for Ⅰ B2 phase, Ⅱ A period, Ⅱ B phase patients no difference in efficacy. For patients with squamous cell carcinoma and adenocarcinoma no difference in efficacy (due to adenocarcinoma of only one case, to a certain extent affect the statistical accuracy). For different pathological grade of no significant difference in patient outcomes. (3) two kinds of ways of neoadjuvant chemotherapy can effectively reduce the maximum tumor diameter; through the femoral artery chemotherapy, intravenous chemotherapy tumor shrinkage than the more obvious; through the femoral artery in patients with postoperative chemotherapy pathologic vascular invasion rate is lower than intravenous chemotherapy after surgery; while both in the vaginal margin, parametrial lymph node-positive rate conditions and no significant difference. (4) through the femoral artery chemotherapy, intravenous chemotherapy than the incidence of bone marrow suppression, gastrointestinal adverse reactions, alopecia response rate is low; chemotherapy drug fever liver damage and adverse reactions occurred, no difference between the two. (5) neoadjuvant chemotherapy group after surgery rate of vascular invasion and lymph node-positive rate of less than immediate surgery group. Conclusions: (1) neoadjuvant chemotherapy on various stages, tumor type, histological grade of cervical cancer are valid. (2) cervical cancer neoadjuvant chemotherapy can effectively reduce the maximum tumor diameter, suitable for radical surgery to get the chance, femoral artery aneurysm and postoperative administration reduced vascular infiltration rate lower than after intravenous administration. (3) radical surgery neoadjuvant chemotherapy in patients with vascular invasion and lymph node-positive rates were lower than direct surgical patients. (4) through the femoral artery in patients with chemotherapy administered adverse events were lower than in patients administered intravenously.
|